Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which thyroid test spares more patients from unneeded surgery?

NCT ID NCT02681328

Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two genetic tests, Afirma GSC and ThyroSeq v.3, on tissue from thyroid nodules that have unclear biopsy results. The goal is to see which test better identifies benign nodules, so patients can avoid unnecessary surgery. About 328 participants with indeterminate thyroid nodules are enrolled. The results could help doctors choose the best test to preserve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Molecular diagnostic tests (Afirma GSC and ThyroSeq v.3) on thyroid tissue
What this could lead to
If successful, this could help doctors more accurately identify which thyroid nodules are benign, allowing many patients to safely avoid surgery and preserve their quality of life.
What could go wrong
This is a diagnostic comparison study, not a treatment trial. The tests may not perform as hoped, and results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

328 people

The number who actually took part.

Started

May 2016

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing thyroid fine needle aspiration (FNA) within the University of California, Los Angeles (UCLA) Health System

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a thyroid nodule who have a thyroid biopsy performed at UCLA health will be eligible for the study and consented if they agree to participate. * Patients who have an indeterminate FNA biopsy result (Bethesda category 3 or 4) will be enrolled in the study if they agree to participate. Exclusion Criteria: * Patients who do not have an indeterminate biopsy result (either patients who have a benign, insufficient, or malignant result).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid gland disorder thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid

Contacts and locations

Locations

  • Jonsson Comprehensive Cancer Center at UCLA

    Los Angeles, California, 90095-1781, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.